Physician profile
John L Serrian, JR.
NPI 1336128768
$1,540.92
in general payments reported to CMS, 2019-2025
22 companies · $45.14 in 2025
The $45.14 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $158 · 2021: $177 · 2022: $59.18 · 2023: $59.51 · 2024: $270 · 2025: $45.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $257.74 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $254.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $152.25 | 2019-2022 | |
| Boston Scientific Corporation | $146.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $142.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $86.43 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $84.54 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.87 | 2019 | |
| Amgen INC. | $68.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.11 | 2019-2020 | |
| Lundbeck LLC | $28.49 | 2019 | |
| United Therapeutics Corporation | $26.99 | 2019-2020 | |
| Scpharmaceuticals INC. | $20.88 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $20.40 | 2023 | Inpefa |
| Amarin Pharma, INC. | $17.96 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $17.78 | 2024 | Brilinta |
| Astellas Pharma US INC | $17.13 | 2019 | |
| Vifor Pharma, INC. | $13.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.07 | 2019 | |
| Daiichi Sankyo INC. | $11.52 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Serrian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.